Induction of apoptosis coupled to endoplasmic reticulum stress in human prostate cancer cells by n-butylidenephthalide

PLoS ONE

Volumn 7, Issue 3, 2012, Pages

  Chiu, Sheng Chun ^a   Chen, Shee Ping ^a   Huang, Sung Ying ^b   Wang, Mei Jen ^a   Lin, Shinn Zong ^c   Harn, Horng Jyh ^c   Pang, Cheng Yoong ^a,d  

^a BUDDHIST TZU CHI GENERAL HOSPITAL   (Taiwan)

^b MACKAY MEMORIAL HOSPITAL   (Taiwan)

^c CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^d TZU CHI UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CELL PROTEIN; CHECKPOINT PROTEIN; CYCLIN D; CYCLIN DEPENDENT KINASE 2; GLUCOSE REGULATED PROTEIN 78; GLYCOGEN SYNTHASE KINASE 3BETA; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 153; MITOGEN ACTIVATED PROTEIN KINASE P38; N BUTYLIDENEPHTHALIDE; PROTEIN IRE1 ALPHA; PROTEIN P16; PROTEIN P21; PROTEIN P27; RETINOBLASTOMA PROTEIN; SMALL INTERFERING RNA; STRESS ACTIVATED PROTEIN KINASE 1; UNCLASSIFIED DRUG; BUTYLIDENEPHTHALIDE; CYCLIN DEPENDENT KINASE INHIBITOR 1A; CYCLIN DEPENDENT KINASE INHIBITOR 1B; CYCLIN DEPENDENT KINASE INHIBITOR 2A; DDIT3 PROTEIN, HUMAN; ERN1 PROTEIN, HUMAN; MITOGEN ACTIVATED PROTEIN KINASE 9; PHTHALIC ANHYDRIDE; PROTEIN SERINE THREONINE KINASE; RIBONUCLEASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER SIZE; CELL CYCLE ARREST; CELL VIABILITY; CHOP GENE; CONTROLLED STUDY; ENDOPLASMIC RETICULUM STRESS; G0 PHASE CELL CYCLE CHECKPOINT; G1 PHASE CELL CYCLE CHECKPOINT; GADD153 GENE; GENE; GENE EXPRESSION REGULATION; GENE IDENTIFICATION; GROWTH INHIBITION; HUMAN; HUMAN CELL; MALE; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; OUTCOME ASSESSMENT; PROSTATE CANCER; PROTEIN ANALYSIS; PROTEIN EXPRESSION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TREATMENT DURATION; TUMOR XENOGRAFT; ANIMAL; DRUG ANTAGONISM; DRUG EFFECT; GENETICS; METABOLISM; NONOBESE DIABETIC MOUSE; PROSTATE TUMOR; TUMOR CELL LINE; XENOGRAFT;

MUS;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CYCLIN-DEPENDENT KINASE INHIBITOR P16; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLIN-DEPENDENT KINASE INHIBITOR P27; ENDOPLASMIC RETICULUM STRESS; ENDORIBONUCLEASES; G1 PHASE CELL CYCLE CHECKPOINTS; HUMANS; MALE; MICE; MICE, INBRED NOD; MITOGEN-ACTIVATED PROTEIN KINASE 8; MITOGEN-ACTIVATED PROTEIN KINASE 9; PHTHALIC ANHYDRIDES; PROSTATIC NEOPLASMS; PROTEIN-SERINE-THREONINE KINASES; RNA INTERFERENCE; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTOR CHOP; TRANSPLANTATION, HETEROLOGOUS;

EID: 84859018952     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0033742     Document Type: Article

References (39)

1. Hayat MJ, Howlader N, Reichman ME, Edwards BK, (2007) Cancer statistics, trends, and multiple primary cancer analyses from the Surveillance, Epidemiology, and End Results (SEER) Program. Oncologist 12: 20-37.
2. Xiao H, Verdier-Pinard P, Fernandez-Fuentes N, Burd B, Angeletti R, et al. (2006) Insights into the mechanism of microtubule stabilization by Taxol. Proc Natl Acad Sci U S A 103: 10166-10173.
3. Schiff PB, Fant J, Horwitz SB, (1979) Promotion of microtubule assembly in vitro by taxol. Nature 277: 665-667.
4. Wang H, Chen R, Xu H, (1998) [Chemical constituents of radix Angelicae Sinensis]. Zhongguo Zhong Yao Za Zhi 23: 167-168 inside backcover.
5. Tsai NM, Chen YL, Lee CC, Lin PC, Cheng YL, et al. (2006) The natural compound n-butylidenephthalide derived from Angelica sinensis inhibits malignant brain tumor growth in vitro and in vivo. J Neurochem 99: 1251-1262.
6. Tsai NM, Lin SZ, Lee CC, Chen SP, Su HC, et al. (2005) The antitumor effects of Angelica sinensis on malignant brain tumors in vitro and in vivo. Clin Cancer Res 11: 3475-3484.
7. Wei CW, Lin CC, Yu YL, Lin CY, Lin PC, et al. (2009) n-Butylidenephthalide induced apoptosis in the A549 human lung adenocarcinoma cell line by coupled down-regulation of AP-2alpha and telomerase activity. Acta Pharmacol Sin 30: 1297-1306.
8. Ron D, (2002) Translational control in the endoplasmic reticulum stress response. J Clin Invest 110: 1383-1388.
9. Ma Y, Hendershot LM, (2004) The role of the unfolded protein response in tumour development: friend or foe? Nat Rev Cancer 4: 966-977.
10. Hetz C, Bernasconi P, Fisher J, Lee AH, Bassik MC, et al. (2006) Proapoptotic BAX and BAK modulate the unfolded protein response by a direct interaction with IRE1alpha. Science 312: 572-576.
11. Oyadomari S, Mori M, (2004) Roles of CHOP/GADD153 in endoplasmic reticulum stress. Cell Death Differ 11: 381-389.
12. Ma Y, Brewer JW, Diehl JA, Hendershot LM, (2002) Two distinct stress signaling pathways converge upon the CHOP promoter during the mammalian unfolded protein response. J Mol Biol 318: 1351-1365.
13. Martin SJ, Green DR, (1995) Protease activation during apoptosis: death by a thousand cuts? Cell 82: 349-352.
14. McCullough KD, Martindale JL, Klotz LO, Aw TY, Holbrook NJ, (2001) Gadd153 sensitizes cells to endoplasmic reticulum stress by down-regulating Bcl2 and perturbing the cellular redox state. Mol Cell Biol 21: 1249-1259.
15. Aggarwal BB, Shishodia S, (2006) Molecular targets of dietary agents for prevention and therapy of cancer. Biochem Pharmacol 71: 1397-1421.
16. Chen YL, Jian MH, Lin CC, Kang JC, Chen SP, et al. (2008) The induction of orphan nuclear receptor Nur77 expression by n-butylenephthalide as pharmaceuticals on hepatocellular carcinoma cell therapy. Mol Pharmacol 74: 1046-1058.
17. Sherr CJ, Roberts JM, (1995) Inhibitors of mammalian G1 cyclin-dependent kinases. Genes Dev 9: 1149-1163.
18. Reed SI, Bailly E, Dulic V, Hengst L, Resnitzky D, et al. (1994) G1 control in mammalian cells. J Cell Sci Suppl 18: 69-73.
19. Dobashi Y, Takehana T, Ooi A, (2003) Perspectives on cancer therapy: cell cycle blockers and perturbators. Curr Med Chem 10: 2549-2558.
20. Altomare DA, Testa JR, (2005) Perturbations of the AKT signaling pathway in human cancer. Oncogene 24: 7455-7464.
21. Tokunaga E, Oki E, Egashira A, Sadanaga N, Morita M, et al. (2008) Deregulation of the Akt pathway in human cancer. Curr Cancer Drug Targets 8: 27-36.
22. Diehl JA, (2002) Cycling to cancer with cyclin D1. Cancer Biol Ther 1: 226-231.
23. Ong CS, Zhou J, Ong CN, Shen HM, (2010) Luteolin induces G1 arrest in human nasopharyngeal carcinoma cells via the Akt-GSK-3beta-Cyclin D1 pathway. Cancer Lett 298: 167-175.
24. Caputi M, Groeger AM, Esposito V, Dean C, De Luca A, et al. (1999) Prognostic role of cyclin D1 in lung cancer. Relationship to proliferating cell nuclear antigen. Am J Respir Cell Mol Biol 20: 746-750.
25. Gumbiner LM, Gumerlock PH, Mack PC, Chi SG, deVere White RW, et al. (1999) Overexpression of cyclin D1 is rare in human prostate carcinoma. Prostate 38: 40-45.
26. Ranganathan AC, Ojha S, Kourtidis A, Conklin DS, Aguirre-Ghiso JA, (2008) Dual function of pancreatic endoplasmic reticulum kinase in tumor cell growth arrest and survival. Cancer Res 68: 3260-3268.
27. Ron D, Walter P, (2007) Signal integration in the endoplasmic reticulum unfolded protein response. Nat Rev Mol Cell Biol 8: 519-529.
28. Li B, Gao B, Ye L, Han X, Wang W, et al. (2007) Hepatitis B virus X protein (HBx) activates ATF6 and IRE1-XBP1 pathways of unfolded protein response. Virus Res 124: 44-49.
29. Lin JH, Li H, Yasumura D, Cohen HR, Zhang C, et al. (2007) IRE1 signaling affects cell fate during the unfolded protein response. Science 318: 944-949.
30. Moenner M, Pluquet O, Bouchecareilh M, Chevet E, (2007) Integrated endoplasmic reticulum stress responses in cancer. Cancer Res 67: 10631-10634.
31. Marciniak SJ, Yun CY, Oyadomari S, Novoa I, Zhang Y, et al. (2004) CHOP induces death by promoting protein synthesis and oxidation in the stressed endoplasmic reticulum. Genes Dev 18: 3066-3077.
32. Fu HY, Okada K, Liao Y, Tsukamoto O, Isomura T, et al. (2010) Ablation of C/EBP homologous protein attenuates endoplasmic reticulum-mediated apoptosis and cardiac dysfunction induced by pressure overload. Circulation 122: 361-369.
33. Nieto-Miguel T, Fonteriz RI, Vay L, Gajate C, Lopez-Hernandez S, et al. (2007) Endoplasmic reticulum stress in the proapoptotic action of edelfosine in solid tumor cells. Cancer Res 67: 10368-10378.
34. Herbst RS, Eckhardt SG, Kurzrock R, Ebbinghaus S, O'Dwyer PJ, et al. (2010) Phase I dose-escalation study of recombinant human Apo2L/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancer. J Clin Oncol 28: 2839-2846.
35. Camidge DR, Herbst RS, Gordon MS, Eckhardt SG, Kurzrock R, et al. (2010) A phase I safety and pharmacokinetic study of the death receptor 5 agonistic antibody PRO95780 in patients with advanced malignancies. Clin Cancer Res 16: 1256-1263.
36. Griffith TS, Stokes B, Kucaba TA, Earel JK Jr, VanOosten RL, et al. (2009) TRAIL gene therapy: from preclinical development to clinical application. Curr Gene Ther 9: 9-19.
37. Bellail AC, Qi L, Mulligan P, Chhabra V, Hao C, (2009) TRAIL agonists on clinical trials for cancer therapy: the promises and the challenges. Rev Recent Clin Trials 4: 34-41.
38. Pei Z, Chu L, Zou W, Zhang Z, Qiu S, et al. (2004) An oncolytic adenoviral vector of Smac increases antitumor activity of TRAIL against HCC in human cells and in mice. Hepatology 39: 1371-1381.
39. Shankar S, Srivastava RK, (2004) Enhancement of therapeutic potential of TRAIL by cancer chemotherapy and irradiation: mechanisms and clinical implications. Drug Resist Updat 7: 139-156.